Results 41 to 50 of about 1,391,378 (297)
Boundary‐Dependent Sleep–Wake Dysregulation in Idiopathic Hypersomnia
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Idiopathic hypersomnia (IH) presents with excessive daytime sleepiness (EDS) despite apparently preserved nocturnal sleep, challenging traditional models of hypersomnolence based on sleep loss or fragmentation. We aimed to test the hypothesis that EDS in IH reflects excessive stabilization of the sleep state, consistent with ...
Samantha Mombelli +13 more
wiley +1 more source
Pharmacology Research & Perspectives, 2022 Morphine is frequently applied in cancer patients for pain management. However, its effects on cancer are not well understood but observed to be specific to certain cancer types. We previously revealed the stimulatory properties of morphine in esophageal
Zhengwen Yu +3 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective The concern that nonsteroidal anti‐inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing musculoskeletal symptoms in those with IBD, but safety data are mixed. Methods This retrospective cohort study included patients with IBD aged at least 18 years from Optum's deidentified ...
Adam S. Mayer +4 more
wiley +1 more source
Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus
Arthritis Care &Research, EarlyView.Objective Individuals with systemic lupus erythematosus (SLE) can accumulate functional status (FS) impairment. We evaluated the association between neighborhood socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), and FS in a national SLE sample.
Baljeet Rai +7 more
wiley +1 more source
Molecular Pain, 2016 Despite mu opioid receptor agonists are the cornerstones of moderate-to-severe acute pain treatment, their effectiveness in chronic pain conditions is controversial.
Nunzio Vicario PhD (cand) +6 more
doaj +1 more source
Butorphanol: Effects of a Prototypical Agonist-Antagonist Analgesic on κ-Opioid Receptors
Journal of Pharmacological Sciences, 2005 The opioid analgesic, butorphanol (17-cyclobutylmethyl-3,14-dihydroxymorphinan) tartrate is a prototypical agonist-antagonist opioid analgesic agent whose potential for abuse has been the cause of litigation in the United States.
Stephen Commiskey +3 more
doaj +1 more source
Molecules, 2020 Achieving effective pain management is one of the major challenges associated with modern day medicine. Opioids, such as morphine, have been the reference treatment for moderate to severe acute pain not excluding chronic pain modalities.
Abdelfattah Faouzi +2 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective We characterized emergency department (ED) gout visits and identified patient characteristics and health services patterns contributing to ED presentations. Methods We conducted a population‐based study of ED gout visits in Ontario, Canada, between 2014 and 2023.
Timothy S. H. Kwok +7 more
wiley +1 more source
Molecular Perspectives for mu/delta Opioid Receptor Heteromers as Distinct, Functional Receptors
Cells, 2014 Opioid receptors are the sites of action for morphine and the other opioid drugs. Abundant evidence now demonstrates that different opioid receptor types can physically associate to form heteromers.
Edmund W. Ong, Catherine M. Cahill
doaj +1 more source
Opioid and cannabinoid receptors
Current Opinion in Neurobiology, 1994 Opioids and cannabinoids are two major classes of drugs with important clinical uses as well as significant side effects. Recently, the three major subtypes of opioid receptors, delta, kappa and mu, have been cloned. Both the endogenous cannabinoids and their receptors have also recently been cloned.
T, Reisine, M J, Brownstein
openaire +2 more sources